Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Final results of a prospective multi-institutional phase ii study of everolimus (rad001), an mtor inhibitor, in pediatric patients with recurrent or progressive low-grade glioma. A poetic consortium trial.

Final results of a prospective multi-institutional phase ii study of everolimus (rad001), an mtor inhibitor, in pediatric patients with recurrent or progressive low-grade glioma. A poetic consortium trial. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii27.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.